PGR and breast cancer: The BC subtypes represented in our patient cohort were: 5 luminal types, 5 luminal/loss meaning that the metastatic sites lost their estrogen or progesterone receptor expression, 5 basal-like types, 1 HER2+ and 1 HER2+/loss (Supplemental Methods, Section 3).